更新于：2024-06-24
Gadobenate Dimeglumine
钆贝葡胺
更新于：2024-06-24
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2003-07-07), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C29H44GdN4O16 |
InChIKeyCJORWGYBYNJSPN-BMWGJIJESA-J |
CAS号127000-20-8 |
关联
31
项与 钆贝葡胺 相关的临床试验Phase II Study of 18F-FFNP Breast PET/MRI in the Assessment of Early Response of Breast Cancer to Presurgical Endocrine Therapy
Active Surveillance Study of the Safety of MultiHance®in India.
Phase II Study to Evaluate the Performance of PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Clinically Significant Prostate Cancer in Men Presenting Following a Positive Screen for Prostate Cancer
100 项与 钆贝葡胺 相关的临床结果
登录后查看更多信息
100 项与 钆贝葡胺 相关的转化医学
登录后查看更多信息
100 项与 钆贝葡胺 相关的专利（医药）
登录后查看更多信息
829
项与 钆贝葡胺 相关的文献（医药）2024-03-01Biomaterials
Metallic artifacts-free spectral computed tomography angiography based on renal clearable bismuth chelate
Article
作者: Zhao, Lu ; Jiang, Yingjian ; Shu, Gang ; Sun, Shao-Kai ; Pan, Jinbin ; Zhang, Xuening ; Li, Fengtan ; Yu, Chunshui
Computed tomography angiography (CTA) is one of the most important diagnosis techniques for various vascular diseases in clinic. However, metallic artifacts caused by metal implants and calcified plaques in more and more patients severely hinder its wide applications. Herein, we propose an improved metallic artifacts-free spectral CTA technique based on renal clearable bismuth chelate (Bi-DTPA dimeglumine) for the first time. Bi-DTPA dimeglumine owns the merits of ultra-simple synthetic process, approximately 100% of yield, large-scale production capability, good biocompatibility, and favorable renal clearable ability. More importantly, Bi-DTPA dimeglumine shows superior contrast-enhanced effect in CTA compared with clinical iohexol at a wide range of X-ray energies especially in higher X-ray energy. In rabbits' model with metallic transplants, Bi-DTPA dimeglumine assisted-spectral CTA can not only effectively mitigate metallic artifacts by reducing beam hardening effect under high X-ray energy, but also enables accurate delineation of vascular structure. Our proposed strategy opens a revolutionary way to solve the bottleneck problem of metallic artifacts in CTA examinations.
European radiology
Liver Imaging Reporting and Data System version 2018 category 5 for diagnosing hepatocellular carcinoma: an updated meta-analysis
Article
作者: Choi, Jin-Young ; Kim, Yeun-Yoon ; Chernyak, Victoria ; Lee, Sunyoung ; Shin, Jaeseung ; Sirlin, Claude B ; Roh, Yun Ho
OBJECTIVE:
We performed an updated meta-analysis to determine the diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS, LR) 5 category for hepatocellular carcinoma (HCC) using LI-RADS version 2018 (v2018), and to evaluate differences by imaging modalities and type of MRI contrast material.
METHODS:
The MEDLINE and Embase databases were searched for studies reporting the performance of LR-5 using v2018 for diagnosing HCC. A bivariate random-effects model was used to calculate the pooled per-observation sensitivity and specificity. Subgroup analysis was performed based on imaging modalities and type of MRI contrast material.
RESULTS:
Forty-eight studies qualified for the meta-analysis, comprising 9031 patients, 10,547 observations, and 7216 HCCs. The pooled per-observation sensitivity and specificity of LR-5 for diagnosing HCC were 66% (95% CI, 61-70%) and 91% (95% CI, 89-93%), respectively. In the subgroup analysis, MRI with extracellular agent (ECA-MRI) showed significantly higher pooled sensitivity (77% [95% CI, 70-82%]) than CT (66% [95% CI, 58-73%]; p = 0.023) or MRI with gadoxetate (Gx-MRI) (65% [95% CI, 60-70%]; p = 0.001), but there was no significant difference between ECA-MRI and MRI with gadobenate (gadobenate-MRI) (73% [95% CI, 61-82%]; p = 0.495). Pooled specificities were 88% (95% CI, 80-93%) for CT, 92% (95% CI, 86-95%) for ECA-MRI, 93% (95% CI, 91-95%) for Gx-MRI, and 91% (95% CI, 84-95%) for gadobenate-MRI without significant differences (p = 0.084-0.803).
CONCLUSIONS:
LI-RADS v2018 LR-5 provides high specificity for HCC diagnosis regardless of modality or contrast material, while ECA-MRI showed higher sensitivity than CT or Gx-MRI.
CLINICAL RELEVANCE STATEMENT:
Refinement of the criteria for improving sensitivity while maintaining high specificity of LR-5 for HCC diagnosis may be an essential future direction.
KEY POINTS:
• The pooled per-observation sensitivity and specificity of LR-5 for diagnosing HCC using LI-RADSv2018 were 66% and 91%, respectively. • ECA-MRI showed higher sensitivity than CT (77% vs 66%, p = 0.023) or Gx-MRI (77% vs 65%, p = 0.001). • LI-RADS v2018 LR-5 provides high specificity (88-93%) for HCC diagnosis regardless of modality or contrast material type.
2024-02-01Investigative radiology
A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body
Review
作者: Pitrou, Camille ; Hao, Jing ; Bourrinet, Philippe
Abstract:
This review describes the pharmacokinetics, efficacy, and safety of gadopiclenol, a new macrocyclic gadolinium-based contrast agent (GBCA) recently approved by the Food and Drug Administration at the dose of 0.05 mmol/kg. Gadopiclenol is a high relaxivity contrast agent that shares similar pharmacokinetic characteristics with other macrocyclic GBCAs, including a predominant renal excretion. In pediatric patients aged 2–17 years, the pharmacokinetic parameters (assessed through a population pharmacokinetics model) were comparable to those observed in adults, indicating no need for age-based dose adjustment. For contrast-enhanced magnetic resonance imaging (MRI) of the central nervous system (CNS) and body indications, gadopiclenol at 0.05 mmol/kg was shown to be noninferior to gadobutrol at 0.1 mmol/kg in terms of 3 lesion visualization parameters (ie, lesion border delineation, internal morphology, and contrast enhancement). Moreover, for contrast-enhanced MRI of the CNS, compared with gadobenate dimeglumine at 0.1 mmol/kg, gadopiclenol exhibited superior contrast-to-noise ratio at 0.1 mmol/kg and comparable contrast-to-noise ratio at 0.05 mmol/kg. A pooled safety analysis of 1047 participants showed a favorable safety profile for gadopiclenol. Comparative studies showed that the incidence and nature of adverse drug reactions with gadopiclenol were comparable to those observed with other GBCAs. Importantly, no significant safety concerns were identified in pediatric and elderly patients, as well as in patients with renal impairment. Overall, these findings support the clinical utility and safety of gadopiclenol for MRI in adult and pediatric patients aged 2 years and older in CNS and body indications.
100 项与 钆贝葡胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 动脉闭塞性疾病 | 美国 | 2012-07-06 | |
| 中枢神经系统疾病 | 澳大利亚 | 2003-07-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 颈动脉疾病 | 临床3期 | 中国 | 2009-09-01 | |
| 肾脏疾病 | 临床3期 | 中国 | 2009-09-01 | |
| 外周动脉疾病 | 临床3期 | 中国 | 2009-09-01 | |
| 外周血管疾病 | 临床3期 | 意大利 | 2006-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 30 | 憲範膚鏇鹽衊醖製餘鏇(鑰獵齋艱鏇願築鑰憲醖) = 憲蓋齋憲膚築窪艱獵餘 蓋觸鏇獵獵齋艱餘衊範 (憲壓壓選襯顧壓簾築網, 糧範願鹽窪齋遞鹽鏇繭 ~ 窪淵網積淵淵範齋鹹艱) 更多 | - | 2017-11-07 | |||
临床3期 | - | 46 | 淵窪積艱鑰廠構顧網壓(醖鹽齋餘鏇選範齋壓壓) = 齋構艱簾製壓餘鏇齋願 選繭餘築憲選夢製選鏇 (鬱餘憲壓艱獵網膚鑰願 ) 更多 | 积极 | 2013-04-01 | ||
淵窪積艱鑰廠構顧網壓(醖鹽齋餘鏇選範齋壓壓) = 鹽觸鹹憲衊蓋範顧蓋蓋 選繭餘築憲選夢製選鏇 (鬱餘憲壓艱獵網膚鑰願 ) 更多 | |||||||
临床3期 | - | 觸獵選製淵選衊繭製餘(艱觸膚齋艱襯齋膚鹽蓋) = 齋繭壓願齋襯網網網顧 積襯鏇鬱網艱簾夢鬱窪 (襯襯簾醖鑰糧鏇鬱憲艱 ) 更多 | 积极 | 2011-02-01 | |||
觸獵選製淵選衊繭製餘(艱觸膚齋艱襯齋膚鹽蓋) = 餘觸築顧築鬱簾齋範繭 積襯鏇鬱網艱簾夢鬱窪 (襯襯簾醖鑰糧鏇鬱憲艱 ) 更多 | |||||||
临床3期 | 92 | 蓋衊膚遞餘衊憲繭構壓(鬱鹹憲鹽憲選膚鹽繭積) = 顧鹹蓋繭簾糧簾觸選繭 獵製簾網淵壓窪獵鑰夢 (繭簾鹽願淵淵廠餘淵鬱, 築憲醖夢獵網衊艱壓壓 ~ 範衊襯鹹簾憲壓醖範艱) 更多 | - | 2010-10-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用